KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
12.9 nM 2.5 μM 9.3 μM 16.6 μM >100 μM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq3TWM2OD1|LkK3N|UzKM7:TR?= MmPuV2FPT0WU
HuO-3N1 M2frcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknFTWM2OD12LkG3NVQzKM7:TR?= NGnlT4FUSU6JRWK=
LAMA-84 NYjRXm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\MTIJqUUN3ME20MlU5PDZ3IN88US=> NWD5W2FQW0GQR1XS
CAL-72 NUX1NHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LvNGlEPTB;NT60PFA5PCEQvF2= MnjiV2FPT0WU
LoVo MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrWTWM2OD14LkmzNlM6KM7:TR?= MYPTRW5ITVJ?
HH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli5TWM2OD16LkK3OlcyKM7:TR?= NF3WOmhUSU6JRWK=
SK-MEL-3 M{j2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvIOmZRUUN3ME24MlI5PTd3IN88US=> NHrzdG5USU6JRWK=
KM12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X6UmlEPTB;OT6yNVE1OiEQvF2= MljHV2FPT0WU
NCI-H1437 NY\3cpZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fTRWlEPTB;OT64NFk4KM7:TR?= MYfTRW5ITVJ?
NCI-H1838 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LQWWlEPTB;MUGuNVg3PSEQvF2= M3;kNnNCVkeHUh?=
J-RT3-T3-5 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHPTWM2OD1zMT6yOFE4KM7:TR?= NUH1WppvW0GQR1XS
GOTO MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjBd4hSUUN3ME2xNU43QTl4IN88US=> Ml;SV2FPT0WU
LB2241-RCC M3v5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1zMT63NVg3KM7:TR?= Mm\TV2FPT0WU
ES7 M1uyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jaSGlEPTB;MUGuO|g5KM7:TR?= MYLTRW5ITVJ?
KP-N-YS MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHDbnpKSzVyPUGyMlY{PTRizszN MYXTRW5ITVJ?
CAL-12T NG\WcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnYb2tRUUN3ME2xN{43OTdizszN Mm\tV2FPT0WU
COLO-684 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W1ZmlEPTB;MUSuNVU3QSEQvF2= MlzXV2FPT0WU
DOK M4fjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHzTWM2OD1zNT6zN|I6KM7:TR?= MWDTRW5ITVJ?
Hs-578-T M3j4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf0TWM2OD1zNT60NVgzKM7:TR?= MUPTRW5ITVJ?
D-423MG MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHTWM2OD1zNT61NlM3KM7:TR?= M4C2WHNCVkeHUh?=
DBTRG-05MG M{XXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzuZZlqUUN3ME2xOU43OTFzIN88US=> NXGxS|dwW0GQR1XS
VM-CUB-1 NGq0eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3Lkm4OFkh|ryP M1SwVXNCVkeHUh?=
KG-1 NFj6XIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXVTWM2OD1zNj6wPVk3KM7:TR?= NEX6bI1USU6JRWK=
8305C MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXZd4dKSzVyPUG2MlE5QDlizszN MWPTRW5ITVJ?
HuH-7 NFi5XI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4iwbGlEPTB;MU[uNlY4PCEQvF2= Mlq3V2FPT0WU
LXF-289 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILDWIhKSzVyPUG2MlI4PDdizszN MUHTRW5ITVJ?
NCI-H1793 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF4LkS3NVIh|ryP Mnr6V2FPT0WU
ChaGo-K-1 NIXufHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHyTWZQUUN3ME2xOk43PTZ6IN88US=> M1H0O3NCVkeHUh?=
GCIY MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3kTWM2OD1zNj63PVA2KM7:TR?= NFjJSlZUSU6JRWK=
SK-MEL-28 NHrkT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyxTXVKSzVyPUG3MlA1PzVizszN M4HBeXNCVkeHUh?=
NCI-SNU-1 NGHqOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Q[mlEPTB;MUeuNVI3QSEQvF2= M{nyenNCVkeHUh?=
CTB-1 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TaRWlEPTB;MUeuNlI2QSEQvF2= Ml3GV2FPT0WU
NCI-H82 MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXse4VKSzVyPUG3MlQ2PzNizszN MVXTRW5ITVJ?
HCC2998 M1jRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\MfWR7UUN3ME2xO{43PzN|IN88US=> MV;TRW5ITVJ?
NCI-H2030 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DiUmlEPTB;MUiuNVk6PyEQvF2= NH2xOohUSU6JRWK=
HuP-T3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF6LkW4PFgh|ryP M4naRnNCVkeHUh?=
697 M1LPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PH[GlEPTB;MUmuNFIxOSEQvF2= NEDhc45USU6JRWK=
MLMA NIfobXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD1zOT6wOVU4KM7:TR?= NWHEfFQ3W0GQR1XS
HCC70 M3rIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJeYZKSzVyPUG5MlQ5QSEQvF2= Ml3zV2FPT0WU
A704 M13nVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXjTWM2OD1zOT64N|A2KM7:TR?= NHXvd2FUSU6JRWK=
D-283MED Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJyLkWzN|kh|ryP MXHTRW5ITVJ?
U031 M3jn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXRcHc1UUN3ME2yNU4yPDh7IN88US=> M2\pZnNCVkeHUh?=
HSC-3 NIfSXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjkWmVKSzVyPUKxMlE5OzVizszN MV7TRW5ITVJ?
JVM-3 NVvBeJJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG0TWM2OD1{Mj61NFYh|ryP M1vYVnNCVkeHUh?=
Mewo M2\Cbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHxVYtKSzVyPUKyMlUxPzNizszN M1j2d3NCVkeHUh?=
YH-13 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17BV2lEPTB;MkKuOVEzOyEQvF2= MlH4V2FPT0WU
LB1047-RCC NHqyPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ{LkW4O|kh|ryP MWLTRW5ITVJ?
HCC2157 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHIbZVKSzVyPUKyMlgxPTRizszN NY[wOoJOW0GQR1XS
SNU-449 NXPl[G5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ{Lki3OFgh|ryP NXj0c2RUW0GQR1XS
Ramos-2G6-4C10 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ{Lkm2JO69VQ>? MoLxV2FPT0WU
CHL-1 NXPxXWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ|LkeyPVIh|ryP NXu3SlFKW0GQR1XS
SK-MEL-30 NXqzNGhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe0[ZJKSzVyPUK0MlQ3PjJizszN MW\TRW5ITVJ?
PANC-08-13 NEfRT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHXU|NKSzVyPUK1MlA6OzhizszN M3Pt[HNCVkeHUh?=
QIMR-WIL M3PMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHzR49KSzVyPUK1MlE5PThizszN M{PVd3NCVkeHUh?=
BFTC-905 NIK3R3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkiwTWM2OD1{NT61PVQ1KM7:TR?= Ml;lV2FPT0WU
GI-1 NVTCXZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:0eWlEPTB;MkWuO|A2PSEQvF2= MWTTRW5ITVJ?
MDA-MB-415 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrCeohKSzVyPUK2MlUxOzNizszN NF6wdWpUSU6JRWK=
GT3TKB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;FVGlEPTB;Mk[uOVM1OiEQvF2= MnT2V2FPT0WU
DEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTvfGVZUUN3ME2yOk45OzV4IN88US=> NG\4XWZUSU6JRWK=
KOSC-2 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfCTWM2OD1{Nj65NFc2KM7:TR?= M4DSdHNCVkeHUh?=
RVH-421 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHFTWM2OD1{Nz6yPVIyKM7:TR?= NU[3PXl3W0GQR1XS
EW-13 NELxSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HxNGlEPTB;MkeuOFMxQCEQvF2= NFzTVFRUSU6JRWK=
639-V NHXLXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ5LkWxNVkh|ryP MorwV2FPT0WU
A2780 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH3TXdKSzVyPUK3MlY1OSEQvF2= M3i3NXNCVkeHUh?=
SW982 NGTGOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS3VW5KSzVyPUK3MlkxPTJizszN NVfmV2o4W0GQR1XS
SW1710 NYH0fox[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHxRYxkUUN3ME2yPE4xQThzIN88US=> NIfWb3pUSU6JRWK=
HCC1569 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jjemlEPTB;MkiuOFg6PyEQvF2= Mlq4V2FPT0WU
MV-4-11 NH;FU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ6LkW3N|Uh|ryP MYDTRW5ITVJ?
BHT-101 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PDfmlEPTB;MkiuOlU4OiEQvF2= NHj5eG1USU6JRWK=
Ca9-22 NXjhZYpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0T2lEPTB;MkiuO|E1KM7:TR?= NV3uNWg2W0GQR1XS
HAL-01 NUXF[XBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq3TWM2OD1{OD63OlE2KM7:TR?= NHzVT4ZUSU6JRWK=
D-263MG NHfMRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzaTWM2OD1{OT6zOFQh|ryP MX3TRW5ITVJ?
NEC8 Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjUTplKSzVyPUK5MlU2PDhizszN NHjHNZJUSU6JRWK=
EKVX NYnnVYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf5TWM2OD1|MT61PFQ4KM7:TR?= NF\oeZZUSU6JRWK=
EM-2 NFfFVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISyfmdKSzVyPUOxMlY{ODRizszN M3r5dnNCVkeHUh?=
MFM-223 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEU49KSzVyPUOxMlgxQThizszN M3rJb3NCVkeHUh?=
SK-PN-DW NYX6W4o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPiTWM2OD1|Mj6xOFA3KM7:TR?= Mn;PV2FPT0WU
HuO9 NULlTFJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2OD1|Mj61NlgzKM7:TR?= NELS[21USU6JRWK=
MHH-PREB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LVU2lEPTB;M{KuOlI{PCEQvF2= MoGwV2FPT0WU
OVCAR-4 NEXlOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN{LkizOlMh|ryP NUTtWo1xW0GQR1XS
NCI-H1648 M4rSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\XcZFCUUN3ME2zNk45PjVzIN88US=> MXzTRW5ITVJ?
MKN1 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHQcFlCUUN3ME2zOE4yOTBzIN88US=> MofmV2FPT0WU
KYSE-450 NUj4WmJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;4XZFlUUN3ME2zOE43PDR2IN88US=> NYXFbHEyW0GQR1XS
ES8 NHraTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHuTWM2OD1|ND64PVc2KM7:TR?= MlzMV2FPT0WU
MS-1 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi5W4lKSzVyPUO0Mlk2PTRizszN NIjrPWZUSU6JRWK=
HOP-92 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe4NGpYUUN3ME2zOU46Ojd5IN88US=> MmqyV2FPT0WU
SKG-IIIa MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qxTmlEPTB;M{[uNlU3OSEQvF2= NGLERYNUSU6JRWK=
TE-11 NULkfmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN4LkWyOFMh|ryP NUXZc2FoW0GQR1XS
SK-NEP-1 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN5Lk[3OFQh|ryP NFrj[mtUSU6JRWK=
DB Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN5LkmxPFUh|ryP NEX2dIhUSU6JRWK=
IA-LM MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n3[2lEPTB;M{iuNFI{QSEQvF2= M{THTXNCVkeHUh?=
COLO-829 NG\s[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\DNWlEPTB;M{iuOFE2QSEQvF2= M4fYeHNCVkeHUh?=
TGBC11TKB MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DM[mlEPTB;M{muNVQxQCEQvF2= MWHTRW5ITVJ?
CAL-51 NVjOTmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXlWoZXUUN3ME20NE4xPjF{IN88US=> M4\LVXNCVkeHUh?=
NCI-H2228 M4\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7mNINLUUN3ME20NE4{PjZ{IN88US=> MV3TRW5ITVJ?
C32 NVPz[YNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj1PYJkUUN3ME20NE41ODJ2IN88US=> MV\TRW5ITVJ?
KU-19-19 NFTUZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTRyLke2PFMh|ryP M4LhfXNCVkeHUh?=
KNS-62 NHLDOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjJPZRKSzVyPUSwMlg{QDFizszN M1q2O3NCVkeHUh?=
FADU MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmxTWM2OD12MT6yOVAzKM7:TR?= NHvWU5VUSU6JRWK=
CAL-33 M2PYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtRWxKSzVyPUSyMlY4PDlizszN NVPL[HpnW0GQR1XS
CHP-134 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTR{Lki0PVYh|ryP NHr2TmpUSU6JRWK=
HDLM-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR{LkmwPFQh|ryP MlHIV2FPT0WU
NBsusSR MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR|LkC3NlUh|ryP NWWwWphHW0GQR1XS
SW954 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\SRW93UUN3ME20N{4yODV|IN88US=> MXTTRW5ITVJ?
HCC1806 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTQbZpKSzVyPUSzMlQyOSEQvF2= NGrzU5FUSU6JRWK=
VMRC-RCZ NU\BXHVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vhVGlEPTB;NEOuOFU5PiEQvF2= NGfGWpJUSU6JRWK=
A549 M2jxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLrOHVTUUN3ME20N{46OzFizszN MlrnV2FPT0WU
NKM-1 M3vVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnsTWM2OD12Mz65OVU5KM7:TR?= MoHWV2FPT0WU
DMS-273 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD12ND63OVY4KM7:TR?= M4e2eXNCVkeHUh?=
TYK-nu NWGzZ5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3POTmlEPTB;NEWuNVI{PCEQvF2= Ml7YV2FPT0WU
KALS-1 NVP1XJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR3LkG0OkDPxE1? NU\qV5A6W0GQR1XS
A101D NUP5N3dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETodmFKSzVyPUS1MlQ1PTZizszN NVLuTXNZW0GQR1XS
G-361 M1;yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXK[4RKSzVyPUS2MlIyOzhizszN NYW0NHJ3W0GQR1XS
KARPAS-299 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR4LkO1NVYh|ryP NX[zWIlpW0GQR1XS
RS4-11 NInCVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR4LkW0NkDPxE1? MWnTRW5ITVJ?
HT-1376 NVHlcJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnhTWM2OD12Nj63OFI3KM7:TR?= MVzTRW5ITVJ?
SK-N-AS NEHURppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkeyTWM2OD12Nj63PFIzKM7:TR?= M3rtRXNCVkeHUh?=
MG-63 M4rLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ZZVFKSzVyPUS2MlkxOzZizszN MVjTRW5ITVJ?
EPLC-272H NHm3O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX34bmtUUUN3ME20Ok46PTB|IN88US=> MkLXV2FPT0WU
BALL-1 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKwcFNKSzVyPUS3Mlg{OiEQvF2= NUTLdmljW0GQR1XS
LCLC-97TM1 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPjelJbUUN3ME20PE4zODJizszN NWW5SGhFW0GQR1XS
HO-1-N-1 NV\vTGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjl[3lKSzVyPUS4Mlk3PzZizszN MnLRV2FPT0WU
MFE-280 NX;UdnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonWTWM2OD12OT60OlE4KM7:TR?= MWDTRW5ITVJ?
NCI-H526 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrzcXpKSzVyPUS5MlgyPjNizszN NIS1TpFUSU6JRWK=
D-566MG MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKxTW8xUUN3ME20PU46ODl4IN88US=> NYPzZnhtW0GQR1XS
BB30-HNC NVL3W2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTJ[3NKSzVyPUS5Mlk1QThizszN M4TpWnNCVkeHUh?=
SK-N-DZ NGi4OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTVyLkC0PFEh|ryP NHPNPIpUSU6JRWK=
HepG2  MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TLNlExyqEQvF2= MV6yOEBp NH36ZppjdG:la4OgV2MuUUmLMz3pcoR2[2WmIGOgdIhie2ViYYLy[ZN1 M321Z|I2PTJ5MUKz
HepG2  MmjCSpVv[3Srb36gRZN{[Xl? NGHIe2YyOMLizszN MUWyOEBp MWfzeZBxemW|c3XzJJRp\SCyaH;zdIhwenmuYYTpc45{KG:oIFHUUUBwdiCVZYKxPVgyNCCFaHuxJI9vKFOnckO0OUwhS2itMjDvckBVcHJ4ODygZY5lKEOma{Kgc44hXHm{MUWgbY5lfWOnZDDifUBUSy2LSVmz MnzMNlU2OjdzMkO=
KATO III  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfGbXAzNjVxNT:3MlUh|ryP NFPJeYFFVVOR MYTlcohidmOnczD0bIUhfG:6aXPpeJkhd2Zib3zhdIFzcWJ? NEj1OYozPDh2MUexPC=>
hTCEpi M1;ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNEDPxE1? NHjDRotFVVOR MnvXdJJmfmWwdIOgeIhmKGO7dH;wZZRpcWNiZX\m[YN1KG:oIFjTWk0y MYOyOFM4ODh|NR?=
MCF10A NG\j[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxNEDPxE1? NFj2So4zPCCq NFzVfIZFVVOR NXXXT25meG:2ZX70bYF1\XNidHjlJIN6fG:2b4jpZ4l1gSCxZjDHRS=> NHX5V3kzPDF3MEW5OS=>
HL-60  NIfueZNHfW6ldHnvckBCe3OjeR?= MYmxNEDPxE1? NFjJSJAxNjViaB?= M4jBV2ROW09? M2LUS5Jm\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczMEoB?= MU[yN|k{PDRzMR?=
MCF-7 M1PzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxMVExOM7:TR?= MlH0NlQhcA>? M2TQZmZDWw>? NIPPNZJqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NUPkWJFMOjNzOEWzOFc>
HeLa  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxMVExOM7:TR?= NHLRSnEzPCCq MVfGRnM> M1PzW4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MVyyN|E5PTN2Nx?=
SH-SY5Y MojJSpVv[3Srb36gRZN{[Xl? MoX1NVDDqM7:TdMg NEW5[nozPCCq MUHpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>? Mlf4NlI3Ojd{OUS=
IMR-32 Mom5SpVv[3Srb36gRZN{[Xl? NX3DVIVxOTEEoN88UeKh M331dFI1KGh? NGHaO3dqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= NX3mW5I{OjJ4MkeyPVQ>
A549 NFjpUY5HfW6ldHnvckBCe3OjeR?= NGGz[m0yOMLizszNxsA> MYmxJIg> MW\zeZBxemW|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w MkjFNlI2PTl|MkG=
T47D  MYPGeY5kfGmxbjDBd5NigQ>? MkPWNlDDqG2P MoPzNlQhcA>? MoC2SG1UVw>? M36zeJBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z MWWyNVE1PDhyNR?=
A29 MEF NEi2d45HfW6ldHnvckBCe3OjeR?= NULYN2xEOTEEoN88UeKh MlHYNYg> Ml;oZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> M2DDclIxODV|N{ix
MDA-MB-453  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi1MVQxKM7:TR?= MXq3NkBp NHPpUlNKSzVyIH;mJFExKM7:TR?= NX2wU2p1OjByNUO3PFE>
PC-3 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ROU01OCEQvF2= MkLKO|IhcA>? MUnJR|UxKG:oIEGwJO69VQ>? MWOyNFA2Ozd6MR?=

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:[1]
+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:[1]
+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method: U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
5% DMSO and 47.5% PEG300
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID